<!DOCTYPE html>
<html lang="en"><head>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-html/tabby.min.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/light-border.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.3.340">

  <title>Malaria and Leishmaniasis</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="site_libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="site_libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
    /* CSS for citations */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
    }
    .hanging-indent div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }  </style>
  <link rel="stylesheet" href="site_libs/revealjs/dist/theme/quarto.css" id="theme">
  <link href="site_libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="site_libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="site_libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="site_libs/revealjs/plugin/reveal-chalkboard/font-awesome/css/all.css" rel="stylesheet">
  <link href="site_libs/revealjs/plugin/reveal-chalkboard/style.css" rel="stylesheet">
  <link href="site_libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    margin-bottom: 0.5rem;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" data-background-image="./images_malaria/mosquito.png" class="quarto-title-block center">
  <h1 class="title">Malaria and Leishmaniasis</h1>

<div class="quarto-title-authors">
</div>

</section>
<section id="parasitic-diseases-malaria-and-leishmaniasis" class="slide level2" data-background-image="./images_malaria/mosquito.png" data-background-opacity="0.5">
<h2>Parasitic Diseases: Malaria and Leishmaniasis</h2>
<p><br></p>
<p><br></p>
<p>Russell Lewis <br> Associate Professor, Infectious Diseases <br> Department of Molecular Medicine <br> <br>MEP 2491 Infectious Diseases <br> 2 May 2023 <br> <br> <img data-src="800-unipd.svg" data-fig-align="left" width="300"></p>
</section>
<section id="protozoa-first-animals" class="slide level2">
<h2>Protozoa “first animals”</h2>
<p><br></p>
<table style="width:99%;">
<colgroup>
<col style="width: 17%">
<col style="width: 28%">
<col style="width: 53%">
</colgroup>
<thead>
<tr class="header">
<th>Means of spread</th>
<th><p>Habitat</p>
<p>Extracellular</p></th>
<th>Intracellular</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Insect-borne*</td>
<td>African trypanosome (blood)</td>
<td><p><em>Plasmodium</em> (liver, red blood cells)</p>
<p><em>Leishmania</em> (macrophage)</p>
<p>South-America trypanosome (macrophage, muscle, nerve)</p></td>
</tr>
<tr class="even">
<td>Water-born</td>
<td><p>Amoeba (gut)</p>
<p><em>Giardia</em> (gut)</p>
<p><em>Cryptosporidium</em> (gut)</p>
<p><em>Isospora</em> (gut)</p>
<p><em>Trichomonas</em> (urogenital)</p></td>
<td>Toxoplasma (macrophage)</td>
</tr>
</tbody>
</table>

<aside><div>
<p>The protozoa carried by inset vectors are mainly confined to tropics by the distribution of of the vectors</p>
</div></aside></section>
<section id="world-malaria-day" class="slide level2">
<h2>World Malaria Day</h2>

<img data-src="images_malaria/whomalaria.png" class="r-stretch"><p><br></p>
</section>
<section id="the-pathogen" class="slide level2">
<h2>The pathogen</h2>
<p><br></p>

<img data-src="images_malaria/Plasmodium.png" width="600" class="r-stretch quarto-figure-center"><p class="caption">Apicomplexa group of protozoa- specialized complex of apical organelles (micronemes, rhoptries, dense granules) involved in host invasion</p></section>
<section id="the-vector" class="slide level2">
<h2>The vector</h2>
<p><br></p>

<img data-src="images_malaria/mosquito2.png" width="600" class="r-stretch quarto-figure-center"><p class="caption">Malaria is transmitted by the bite of <em>Plasmodium</em>-infected female mosquitoes of the <em>Anophelus</em> genus</p></section>
<section id="malaria-endemic-regions" class="slide level2">
<h2>Malaria endemic regions</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/map.png" width="800"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="phillips2017">(<a href="#/references" role="doc-biblioref" onclick="">Phillips et al., 2017</a>)</span></p>
</div></aside></section>
<section id="the-impact-of-malaria-on-humans-is-is-staggering" class="slide level2">
<h2>The impact of malaria on humans is <br> is staggering</h2>
<ul>
<li class="fragment"><p>Kills roughly 2000 people per day, most of whom are children in Africa</p></li>
<li class="fragment"><p>The strongest documented force for evolutionary selection in the recent history of the human genome</p>
<ul>
<li class="fragment">Malaria is the evolutionary driving force behind the most common Mendelian diseases of humankind: sickle-cell disease, thalassemia, glucose-6-phosphatase deficiency, and other erythrocyte defects</li>
</ul></li>
<li class="fragment"><p>Malaria was once prevalent throughout much of the inhabited world, but has been eliminated from the USA and Canada, Europe, and Russia (chloroquine-based treatment, large-scale insecticide using DDT)</p>
<ul>
<li class="fragment">Malaria prevalence resurged in tropical countries from the 1970s to the 1990s because of a combination of relaxation of control efforts, increasing antimalarial drug resistance, and insecticide resistance in the mosquito vectors</li>
<li class="fragment">More selective vector control approaches (insecticide bed nets, indoor residual spraying) and the introduction of artemisinin-based regimens have led to an overall reduction in mortality in the last 20 years</li>
</ul></li>
<li class="fragment"><p>Growing resistance to insecticides in mosquitoes (<em>Anopheles gambiae)</em></p></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="phillips2017 kwiatkowski2005">(<a href="#/references" role="doc-biblioref" onclick="">Kwiatkowski, 2005</a>; <a href="#/references" role="doc-biblioref" onclick="">Phillips et al., 2017</a>)</span></p>
</div></aside></section>
<section id="trends-in-malaria-death-rates-in-2021" class="slide level2">
<h2>Trends in Malaria death rates in 2021</h2>
<iframe src="https://ourworldindata.org/grapher/malaria-death-rates-by-age" loading="lazy" style="width: 100%; height: 600px; border: 0px none;"></iframe>
<div>
<p>Source: Our World in Data</p>
</div>
</section>
<section id="malaria-deaths-by-age" class="slide level2">
<h2>Malaria deaths by age</h2>
<iframe src="https://ourworldindata.org/grapher/malaria-deaths-by-age" loading="lazy" style="width: 100%; height: 600px; border: 0px none;"></iframe>
<div>
<p>Source: Our World in Data</p>
</div>
</section>
<section id="airport-or-suitcase-associated-malaria" class="slide level2">
<h2>Airport or “suitcase-associated” malaria</h2>
<p><br></p>

<img data-src="images_malaria/aiportmalaria.png" class="r-stretch quarto-figure-center"><div>
<p><span class="citation" data-cites="tatem2006">(<a href="#/references" role="doc-biblioref" onclick="">Tatem et al., 2006</a>)</span></p>
</div>
</section>
<section id="autochthonous-transmission" class="slide level2">
<h2>Autochthonous transmission</h2>
<p><br></p>
<ul>
<li class="fragment">Airport malaria</li>
<li class="fragment">Asymptomatic donors from endemic areas with low-level parasitaemia
<ul>
<li class="fragment">Blood donors</li>
<li class="fragment">Solid organ transplant</li>
</ul></li>
</ul>
</section>
<section id="cases-in-italy" class="slide level2">
<h2>Cases in Italy</h2>

<img data-src="images_malaria/Malaria_Italy.png" class="r-stretch quarto-figure-center"><p class="caption">“It’s the first time in my 30-year career that I’ve seen a case of malaria originating in Trentino,” said Dr Claudio Paternoster, an infectious diseases specialist at Trento’s Santa Chiara Hospital. Since the 1950s, Italy has not had a malaria problem because mosquito-infested marshes were drained. There is speculation that Sofia might have caught malaria from one of two children treated for it at the Trento hospital after 15 August. They had caught it in Africa, and recovered.</p></section>
<section id="pathogenesis" class="slide level2" data-background-image="./images_malaria/mosquito2.png" data-background-opacity="0.5">
<h2>Pathogenesis</h2>
</section>
<section id="plasmodium-spp.-life-cycle" class="slide level2">
<h2>Plasmodium spp. life cycle</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/lifecycle.png" width="800"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="phillips2017">(<a href="#/references" role="doc-biblioref" onclick="">Phillips et al., 2017</a>)</span></p>
</div></aside></section>
<section id="clinical-presentation" class="slide level2">
<h2>Clinical presentation</h2>
<p><br></p>
<ul>
<li class="fragment">First symptoms are typically experienced 2-4 weeks after mosquito bite</li>
<li class="fragment">Asexual replication in RBCs results in subsequent waves of merozoite and malaria endotoxin release (heamozoin and parasite DNA) → TNF-α and paroxysms of chills, fevers and sweats for several hours followed by extreme fatigue</li>
<li class="fragment">Cycle repeats every:
<ul>
<li class="fragment">24 hours <em>Plasmodium knowlesi</em></li>
<li class="fragment">48 hours <em>Plasmodium falciparam, Plasmodium vivax, Plasmodium ovale</em></li>
<li class="fragment">72 hours <em>Plasmodium malaria</em></li>
</ul></li>
<li class="fragment">Some <em>P. vivax</em> and <em>P. ovale</em> can postpone development in liver as latent forms called hypnozoites (not eradicated by standard therapy e.g., chloroquine) directed against blood stages.</li>
<li class="fragment">Hyponozoite development can resume months to years later leading to relapse
<ul>
<li class="fragment">Relapse can be prevented with primaquine, but only moderately effective</li>
</ul></li>
</ul>
</section>
<section id="five-species-of-plasmodium-infection-in-humans" class="slide level2">
<h2>Five species of <em>Plasmodium</em> infection in humans</h2>
<p><br></p>
<table style="width:99%;">
<colgroup>
<col style="width: 12%">
<col style="width: 8%">
<col style="width: 18%">
<col style="width: 59%">
</colgroup>
<thead>
<tr class="header">
<th><em>Plasmodium spp</em>.</th>
<th>Liver stage</th>
<th>Blood cycle and fever peaks</th>
<th>Disease features</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><em>P. falciprium</em></td>
<td>6-14 days</td>
<td>48h (tertian)</td>
<td>Major complications, fatal without treatment</td>
</tr>
<tr class="even">
<td><em>P. vivax</em></td>
<td>12-17 days</td>
<td>48h (tertian)</td>
<td>Seldom fatal, but can better survive unfavourable temperatures and remain dormant in the liver</td>
</tr>
<tr class="odd">
<td><em>P. malariae</em></td>
<td>13-40 days</td>
<td>72h (quartan)</td>
<td>Nephrotic syndrome</td>
</tr>
<tr class="even">
<td><em>P. ovale</em></td>
<td>9-18 days</td>
<td>48h (tertian)</td>
<td></td>
</tr>
<tr class="odd">
<td><em>P. knowlowsi</em></td>
<td>9-12 days</td>
<td>24h (quotidian)</td>
<td>Southeast Asia, monkey</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</section>
<section id="plasmodium-falciparum" class="slide level2">
<h2><em>Plasmodium falciparum</em></h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/erythrocyteeffect.jpeg"></p>
<figcaption>SEM demonstrating effect of malaria parasite on host erythrocyte</figcaption>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="fairhurstrick2015">(<a href="#/references" role="doc-biblioref" onclick="">Fairhurst, Rick and Wellems, Thomas, 2015</a>)</span></p>
</div></aside></section>
<section id="plasmodium-falciparum-1" class="slide level2">
<h2><em>Plasmodium falciparum</em></h2>
<div>
<ul>
<li><p>Most deadly (1 million deaths per year- anaemia and cerebral malaria)</p></li>
<li><p><em>Sequestration</em>- parasitized RBCs: glomerulonephritis, hypoglycaemia, pulmonary edema</p></li>
<li><p>Almost all deaths are caused by this species</p></li>
</ul>
<p><img data-src="images_malaria/patho1.jpeg" width="800"></p>
</div>
<div>
<p><span class="citation" data-cites="fairhurstrick2015">(<a href="#/references" role="doc-biblioref" onclick="">Fairhurst, Rick and Wellems, Thomas, 2015</a>)</span></p>
</div>
</section>
<section id="cerebral-malaria" class="slide level2">
<h2>Cerebral malaria</h2>
<p><br></p>
<ul>
<li class="fragment">Cerebral malaria (intense sequestration of infected erythrocytes in cerebral microvessels)</li>
<li class="fragment">Ring haemorrhages, perivascular leukocyte infiltrates, thrombin deposition</li>
<li class="fragment">Impairment of local delivery of oxygen and glucose</li>
<li class="fragment">Often does not produce neurological sequelae akin to thrombotic stroke
<ul>
<li class="fragment">Recovery within 48 hours common</li>
</ul></li>
</ul>
</section>
<section id="imaging-findings-cerebral-malaria" class="slide level2">
<h2>Imaging findings cerebral malaria</h2>
<div class="columns">
<div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/mri.png" width="600"></p>
<figcaption>Increased brain volume and increased intracranial pressure</figcaption>
</figure>
</div>
</div><div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/retinopathy.png" width="600"></p>
<figcaption>Malarial retinopathy with white-centred hemorrhages un the optic fundi. Pathognomonic for cerebral malaria</figcaption>
</figure>
</div>
</div>

<aside><div>
<p><span class="citation" data-cites="idro2005">(<a href="#/references" role="doc-biblioref" onclick="">Idro et al., 2005</a>)</span></p>
</div></aside></section>
<section id="malaria--acquired-immunity" class="slide level2">
<h2>Malaria- acquired immunity</h2>
<p><br></p>
<ul>
<li class="fragment"><p>Mediated by IgG antibodies against surface proteins of sporozoite (blocking hepatocyte invasion)</p>
<ul>
<li class="fragment">Antibody-dependent cellular cytotoxicity, opsonisation for uptake, destruction by splenic macrophages, interference with PfEMP-1 mediated cytoadhearence interactions</li>
</ul></li>
<li class="fragment"><p>Immunity not sterilizing, instead “disease-controlling immunity” despite presence of parasites in bloodstream</p></li>
<li class="fragment"><p>Immunity increases with age, cumulative episodes and time living in endemic area</p>
<ul>
<li class="fragment"><p>Short-lived without continued exposure to different <em>P. falciparum</em> variants</p></li>
<li class="fragment"><p>Antigen switching results in new waves of parasitemia, escape from antibody responses</p></li>
<li class="fragment"><p>Disease controlling immunity (premunition) after repeated infection episodes associated with development of antibody repertoire that recognizes the full spectrum PfEMP-1 variant antigens</p>
<p><img data-src="images_malaria/recurrent.jpeg" width="600"></p></li>
</ul></li>
</ul>
</section>
<section id="host-traits-that-influence-disease-severity-besides-blood-disorders" class="slide level2">
<h2>Host traits that influence disease severity <br>(besides blood disorders)</h2>
<p><br></p>
<ul>
<li class="fragment"><p><strong>Splenectomy</strong> - high parasite loads</p>
<ul>
<li class="fragment">Splenomegaly common in malaria (removal of infected erythrocytes) but contributes to anaemia associated with disease</li>
</ul></li>
<li class="fragment"><p><strong>Pregnancy</strong> - parasites that express protein surface variant antigen 2-CSA (chondroitin sulphate-2) attaching to glycoproteins expressed in the placenta …leading to infected red blood cell sequestration in the placenta</p>
<ul>
<li class="fragment">Increased risk of maternal and/or foetal death, miscarriage, inter-uterine growth retardation, low-birth weight, increased newborn mortality</li>
</ul></li>
<li class="fragment"><p><strong>HIV</strong> (higher degree of parasitemia, mortality)</p></li>
<li class="fragment"><p><strong>Tuberculosis</strong></p></li>
</ul>
</section>
<section id="complications-of-malaria" class="slide level2">
<h2>Complications of malaria</h2>
<p><br></p>
<ul>
<li class="fragment"><p><strong>Hypoglycaemia (coma, convulsions)</strong></p>
<ul>
<li class="fragment"><p>Children: Impaired hepatic gluconeogenesis, increased glucose consumption in peripheral tissues and by parasites, <strong>normal insulin levels</strong></p></li>
<li class="fragment"><p>Adults: Hyperinsulinemia due to parasite stimulation of pancreatic islet cells or quinine/quinidine therapy</p></li>
<li class="fragment"><p>Decreased food intake during prodromal period</p></li>
</ul></li>
<li class="fragment"><p><strong>Anaemia</strong></p>
<ul>
<li class="fragment">Intra vascular lysis and phagocytic removal of infected erythrocytes</li>
<li class="fragment">TNF-α associated suppression of erythropoetin</li>
<li class="fragment">Normochromic, normocytic anaemia without robust reticulocyte response</li>
</ul></li>
<li class="fragment"><p><strong>Pulmonary oedema and respiratory distress</strong></p>
<ul>
<li class="fragment">Non-cardiogenic pulmonary oedema due to sequestration of infected erythrocytes → inflammatory response → capillary permeability → pulmonary oedema → hypoxia →acute lung injury → ARDS</li>
<li class="fragment">Dyspnea and increasing respiratory rate are features of impending pulmonary oedema and preclude other clinical (e.g., accessory muscle breathing) and radiologic signs (increased interstitial markings)</li>
<li class="fragment">TNF-α associated suppression of erythropoeitin</li>
<li class="fragment">Normochromic, normocytic anemia without robust reticolocyte response</li>
</ul></li>
<li class="fragment"><p><strong>Pulmonary oedema and respiratory distress</strong></p>
<ul>
<li class="fragment">Non-cardiogenic pulmonary oedema due to sequestration of infected erythromyctes → inflammatory response → capillary permeability → pulmonary oedema → hypoxia →acute lung injury → ARDS</li>
<li class="fragment">Dyspnea and increasing respiratory rate are features of impending pulmonary oedema and preclude other clinical (e.g., accessory muscle breathing) and radiologic signs (increased interstitial markings)</li>
</ul></li>
<li class="fragment"><p><strong>Metabolic (lactic) acidosis</strong></p>
<ul>
<li class="fragment">Reduced delivery of oxygen to tissues from combined effects of anaemia, sequesterization and hypovolemia</li>
<li class="fragment">Shift from aerobic to anaerobic metabolism causes lactate levels to rise</li>
<li class="fragment">Lactate clearance by liver reduced</li>
</ul></li>
<li class="fragment"><p><strong>Acute renal failure</strong></p>
<ul>
<li class="fragment">Less common in children</li>
</ul></li>
</ul>
</section>
<section id="diagnosis-and-screening" class="slide level2" data-background-image="./images_malaria/rings.png" data-background-opacity="0.5">
<h2>Diagnosis and Screening</h2>
</section>
<section id="clinical-history" class="slide level2">
<h2>Clinical History</h2>
<p><br></p>
<ul>
<li class="fragment"><p><strong>Febrile illness</strong> (cyclic paroxysms of chills rigours and fever with drenching night sweats after travel to an endemic area)</p>
<ul>
<li class="fragment"><p>Fever 100%</p></li>
<li class="fragment"><p>Headache 100%</p></li>
<li class="fragment"><p>Weakness 94%</p></li>
<li class="fragment"><p>Profuse night sweats 91%</p></li>
<li class="fragment"><p>Insomnia 61%</p></li>
<li class="fragment"><p>Arthralgias 59%</p></li>
<li class="fragment"><p>Myalgias 56%</p></li>
<li class="fragment"><p>Diarrhoea 13%</p></li>
<li class="fragment"><p>Abdominal cramps 8%</p></li>
</ul></li>
<li class="fragment"><p><strong>Physical exam</strong></p>
<ul>
<li class="fragment">Pallor</li>
<li class="fragment">Hepatosplenomegaly</li>
<li class="fragment">Jaundice, diminished consciousness, convulsions (severe malaria)</li>
<li class="fragment">Less common (rash, lymphadenopathy, pulmonary consolidations)</li>
</ul></li>
</ul>
</section>
<section id="parasites-can-be-detected-on-light-microscope-examination-of-blood-smear" class="slide level2 smaller">
<h2>Parasites can be detected on light microscope examination of blood smear</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/smear.png" width="600"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="phillips2017">(<a href="#/references" role="doc-biblioref" onclick="">Phillips et al., 2017</a>)</span> Microscopic images of parasite-infected red blood cells. Thin blood films showing Plasmodium falciparum (upper panel) and Plasmodium&nbsp;vivax (lower panel) at different stages of blood-stage development. The images are from methanol-fixed thin films that were stained for 30&nbsp;minutes in 5% Giemsa. The samples were taken from Thai and Korean patients with malaria: Ethical Review Committee for Research in Human Subjects, Ministry of Public Health, Thailand (reference no. 4/2549, 6&nbsp;February 2006). The&nbsp;sex symbols represent microgametes (male symbol) and macrogametes (female symbol). ER, early ring stage; ES, early schizont stage; ET, early trophozoite stage; FM,&nbsp;free merozoites; LR, late ring stage; LS, late schizont stage; LT, late trophozoite stage; U, uninfected red blood cell.</p>
</div></aside></section>
<section id="parasitemia" class="slide level2">
<h2>Parasitemia</h2>
<p><br></p>
<ul>
<li class="fragment"><p>Light microscopy of Giemsa-stained blood smears is the accepted standard for diagnosis</p></li>
<li class="fragment"><p>Thick smears concentrate red cell layers 40-fold and used to screen large amounts of blood for parasites- RBCs lyse so parasites are visualized outside red cells</p>
<ul>
<li class="fragment"><p>Parasite density can be calculated by counting the number of parasites per 200 WBCs x 40 = number of parasites per μL blood</p></li>
<li class="fragment"><p>For P. falciparum, initial blood smears may be negative because mature erythrocytes (trophozoites and schizonts are sequestered in peripheral tissues)</p></li>
<li class="fragment"><p>Smear is repeated every 12 hours until diagnosis is ruled in or ruled out</p></li>
</ul></li>
<li class="fragment"><p><strong>Thin smears used to determine <em>Plasmodium</em> species</strong></p></li>
</ul>
</section>
<section id="microscopic-images-of-parasite-infected-red-blood-cells" class="slide level2 smaller">
<h2>Microscopic images of parasite <br>infected red blood cells</h2>
<p><br></p>
<table>
<colgroup>
<col style="width: 77%">
<col style="width: 22%">
</colgroup>
<thead>
<tr class="header">
<th>Description</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Multiple signet-ring <em>P. falciparum</em> trophozoites visualized outside erythrocytes in thick blood smear</td>
<td><img data-src="images_malaria/7a.jpeg"></td>
</tr>
<tr class="even">
<td>Multiply infected erythrocyte containing containing signet-ring <em>P. falciparum</em> trophozytes</td>
<td><img data-src="images_malaria/7b.jpeg"></td>
</tr>
<tr class="odd">
<td>Banana-shaped gametocyte unique to <em>P. falciparum</em></td>
<td><img data-src="images_malaria/7c.jpeg"></td>
</tr>
<tr class="even">
<td>Ameboid trophozoite characteristic of <em>P. vivax</em></td>
<td><img data-src="images_malaria/7d.jpeg"></td>
</tr>
<tr class="odd">
<td><em>P. vivax</em> schizont</td>
<td><img data-src="images_malaria/7e.jpeg"></td>
</tr>
<tr class="even">
<td><em>P. vivax</em> spherical gametocyte</td>
<td><img data-src="images_malaria/7f.jpeg"></td>
</tr>
<tr class="odd">
<td><em>P. ovale</em> trophozoite. Note Shuffner’s dots and ovoid shape of erythrocyte</td>
<td><img data-src="images_malaria/7g.jpeg"></td>
</tr>
<tr class="even">
<td>Characteristic band form trophozoite of <em>P. malariae</em> containing intracellular pigment hemozoin</td>
<td><img data-src="images_malaria/7h.jpeg"></td>
</tr>
</tbody>
</table>

<aside><div>
<p><span class="citation" data-cites="fairhurstrick2015">(<a href="#/references" role="doc-biblioref" onclick="">Fairhurst, Rick and Wellems, Thomas, 2015</a>)</span></p>
</div></aside></section>
<section id="rapid-diagnostic-tests-rdts" class="slide level2">
<h2>Rapid diagnostic tests (RDTs)</h2>
<p><br></p>
<ul>
<li class="fragment"><p><strong>Detection of <em>Plasmodium</em> histidine-rich protein-2 (HRP-2)</strong></p>
<ul>
<li class="fragment"><p>Limited to <em>P. falciparum</em></p></li>
<li class="fragment"><p>Not useful for monitoring treatment response (positive for 28 days)</p></li>
<li class="fragment"><p>Less sensitive at parasite densities of 100-1000/μL (may miss non-immune travellers with symptoms at low parasite densities)</p></li>
</ul></li>
<li class="fragment"><p><strong>Detection of <em>P. falciparum</em> specific lactate dehydrogenase (LDH) and pan-<em>Plasmodium</em> LDH</strong></p>
<ul>
<li class="fragment"><p>Adequate sensitivity for <em>P. vivax, P. ovale,</em> and <em>P. malaria</em> with less sensitivity for <em>P. falciparum</em></p></li>
<li class="fragment"><p>However, positive signal is proportional to <em>P. falciparum</em> parasitaemia, allowing for monitoring of therapeutic response</p></li>
</ul></li>
<li class="fragment"><p><strong>Combination tests of HRP-2/LDH under development</strong></p></li>
<li class="fragment"><p>PCR and quantitative PCR (becoming gold standard)</p>
<ul>
<li class="fragment">Identifies species</li>
<li class="fragment">Detets low levels paracetemia</li>
<li class="fragment">qPCR can be used to monitor therapy</li>
<li class="fragment">Availability in endemic areas?</li>
</ul></li>
</ul>
</section>
<section id="diseases-with-similar-clinical-presentations" class="slide level2">
<h2>Diseases with similar clinical presentations</h2>
<p><br></p>
<ul>
<li class="fragment"><p>Malaria should always fall near the top of the differential for fever in travellers or immigrants who have been in an endemic area in the previous 3 months (and remain in consideration for years afterword)</p></li>
<li class="fragment"><p>Common differential diagnosis:</p>
<ul>
<li class="fragment"><p>Influenzae</p></li>
<li class="fragment"><p>Enteric fever</p></li>
<li class="fragment"><p>Bacteraemia/sepsis</p></li>
<li class="fragment"><p>Classic dengue fever (typically more severe myalgias , shorter incubation of 4-7 days, rash and lymphadenopathy)</p></li>
<li class="fragment"><p>Acute schistosomiasis (Katayama fever-freshwater exposure) urticaria at site of cercarial penetration (usually legs) and eosinophilia</p></li>
<li class="fragment"><p>Leptospirosis (conjunctival suffusion and rash progressing to haemorrhagic manifestations)</p></li>
<li class="fragment"><p>African tick fever (lymphadenitis, multiple inoculation eschars)</p></li>
<li class="fragment"><p>East African trypanosomiasis (sleeping sickness) -red chancre at bite site, posterior cervical lymphadenopathy, rash)</p></li>
<li class="fragment"><p>Yellow fever (conjunctival suffusion, shorter incubation period 3-6 days relative bradycardia). Unlikely in patients who have been vaccinated in last 10 years</p></li>
</ul></li>
</ul>
</section>
<section id="therapy" class="slide level2" data-background-image="./images_malaria/Artemisinin.png" data-background-opacity="0.5">
<h2>Therapy</h2>
</section>
<section id="definition-of-severe-malaria" class="slide level2">
<h2>Definition of severe malaria</h2>
<p><br></p>
<table>
<colgroup>
<col style="width: 7%">
<col style="width: 92%">
</colgroup>
<thead>
<tr class="header">
<th>Manifestations</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Impaired consciousness</td>
<td>Glasgow coma score &lt;11 in adults or Blantyre coma score &lt;3 in children; inability to swallow</td>
</tr>
<tr class="even">
<td>Prostration</td>
<td>Generalized weakness so that a person is unable to sit, stand, or walk without assistance</td>
</tr>
<tr class="odd">
<td>Multiple convulsions</td>
<td>More than two episodes within 24 hours</td>
</tr>
<tr class="even">
<td>Acidosis</td>
<td>A base deficit of &gt;8 mEq/L, a plasma bicarbonate level of &lt;15 mmol/L, or venous plasma lactate ≥5 mmol/L. Clinical indicators of acidosis include rapid, deep, labored breathing.</td>
</tr>
<tr class="odd">
<td>Hypoglycaemia</td>
<td>Blood or plasma glucose &lt;40 mg/dL (&lt;2.2 mmol/L) for children ≥5 years and adults; blood or plasma glucose &lt;54 mg/dL (&lt;3 mmol/L) for children &lt;5 years</td>
</tr>
<tr class="even">
<td>Severe anaemia</td>
<td>Haemoglobin concentration ≤5 g/dL or hematocrit ≤15% in children &lt;12 years of age (&lt;7 g/dL and &lt;20%, respectively, in adults) with parasite count &gt;10,000 parasites/uL</td>
</tr>
<tr class="odd">
<td>Renal impairment</td>
<td>Plasma or serum creatinine &gt;3 mg/dL (265 umol/L) or blood urea &gt;20 mmol/L</td>
</tr>
<tr class="even">
<td>Jaundice</td>
<td>Plasma or serum bilirubin &gt;50 umol/L (3 mg/dL) with one of the following:<br>- Plasmodium fal<em>ciparum parasite coun</em>t &gt;2.5% parasitemia<br>- Plasmodium knowlesi parasite <em>count &gt;20,000 para</em>sites/uL</td>
</tr>
<tr class="odd">
<td>Pulmonary edaema</td>
<td>Radiographically confirmed or oxygen saturation &lt;92% on room air with respiratory rate &gt;30/minute, often with chest indrawing and crepitation on auscultation</td>
</tr>
<tr class="even">
<td>Significant bleeding</td>
<td>Including recurrent or prolonged bleeding (from the nose, gums, or venipuncture sites), hematemesis, or melena</td>
</tr>
<tr class="odd">
<td>Shock</td>
<td>Compensated shock is defined as capillary refill ≥3 seconds or temperature gradient on leg (mid to proximal limb), but no hypotension. Decompensated shock is defined as systolic blood pressure &lt;70 mmHg in children or &lt;80 mmHg in adults, with evidence of impaired perfusion (cool peripheries or prolonged capillary refill).</td>
</tr>
<tr class="even">
<td>Hyperparasitaemia</td>
<td><em>P. falciparum</em>:<br>- In non-immune travelers: parasitemia ≥5%[3]<br>- All patients: parasitemia &gt;10%<br><em>P. knowlesi</em>:<br>- Parasite density &gt;100,000 parasites/uL<br><em>Plasmodium vivax</em>:<br>- No established parasite density thresholds</td>
</tr>
</tbody>
</table>
</section>
<section id="therapy--general-principles" class="slide level2">
<h2>Therapy- General principles</h2>
<p><br></p>
<ul>
<li class="fragment"><p><em>P. falciparum</em> malaria can be fatal if not diagnosed and treated promptly an appropriately</p>
<ul>
<li class="fragment">Especially true for non-immune travellers returning from visits to malaria-endemic areas</li>
</ul></li>
<li class="fragment"><p>Malaria is a disease of protean manifestations, diagnosis is delayed by non-specific clinical presentation and unimpressive normal laboratory tests- especially if blood smears (and available rapid diagnostic tests) are not examined</p></li>
<li class="fragment"><p>Life-threatening manifestation (i.e.&nbsp;convulsions, hypoglycaemia, pulmonary oedema) can develop rapidly in patients who appear well at presentation or respond to antimalarial drugs</p></li>
<li class="fragment"><p>Pregnant women, young children and elderly are at increased risk and should be hospitalized regardless</p></li>
<li class="fragment"><p>If patient develops malaria despite prophylaxis, they should receive a different antimalarial regimen for treatment</p></li>
</ul>
</section>
<section id="drug-treatment-versus-parasitic-life-cycle" class="slide level2">
<h2>Drug treatment versus parasitic life cycle</h2>
<p><br></p>

<img data-src="images_malaria/drugstagecycle.png" class="r-stretch quarto-figure-center"></section>
<section id="artemisinin-parasite-clearance" class="slide level2">
<h2>Artemisinin parasite clearance</h2>
<p><br></p>

<img data-src="images_malaria/artemisinins.png" class="r-stretch quarto-figure-center"><div>
<p><span class="citation" data-cites="dondorp2011">(<a href="#/references" role="doc-biblioref" onclick="">Dondorp et al., 2011</a>)</span></p>
</div>
</section>
<section id="artemisinin-based-combination-therapy-act" class="slide level2">
<h2>Artemisinin-based combination therapy (ACT)</h2>
<p><br></p>
<ul>
<li class="fragment"><p>Low side effect profile</p></li>
<li class="fragment"><p>Potent against all states (asexual forms) of malaria</p></li>
<li class="fragment"><p>Most rapid clearance time relative to other antimalarial drugs</p></li>
<li class="fragment"><p>Administered in combination with second drug that has longer half life to forestall artemisinin resistance</p></li>
</ul>
</section>
<section id="who-recommendations-uncomplicated-malaria-treatment" class="slide level2 smaller">
<h2>WHO recommendations: <br> Uncomplicated malaria treatment</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/act therapy.png" width="800"></p>
</figure>
</div>

<aside><div>
<p>In the absence of resistance to the partner drug, the five recommended ACTs have all been shown to achieve a PCR- adjusted treatment failure rate of 5% in many trials in several settings in both adults and children (high-quality evidence) See WHO guidelines for age and weight-specific dosing and toxicity risks in specific populations. Regimens should not be used for pregnant women in first trimester.</p>
<p><span class="citation" data-cites="worldhealthorganization22a">(<a href="#/references" role="doc-biblioref" onclick="">Organization, 2022</a>)</span></p>
</div></aside></section>
<section id="duration-of-treatment" class="slide level2">
<h2>Duration of treatment</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/duration.png"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="worldhealthorganization22a">(<a href="#/references" role="doc-biblioref" onclick="">Organization, 2022</a>)</span></p>
</div></aside></section>
<section id="treatment-of-pregnant-patients" class="slide level2">
<h2>Treatment of pregnant patients</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/pregnant.png"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="worldhealthorganization22a">(<a href="#/references" role="doc-biblioref" onclick="">Organization, 2022</a>)</span></p>
</div></aside></section>
<section id="relapse-or-recurrence" class="slide level2">
<h2>Relapse or Recurrence</h2>
<ul>
<li class="fragment"><p>Follow-up blood smears should document clearance of parasitemia within 48-72 hours of appropriate therapy. Follow-up smears every 12-24 hours are common.</p></li>
<li class="fragment"><p><strong>Recurrence of <em>P. falciparum</em> malaria can result from re-infection or recrudescence (treatment failure)</strong></p>
<ul>
<li class="fragment"><p>Failure :&lt; 28 days: Persistent fever, parasitemia → treat with another ACT regimen effective in region. Treatment with same ACT considered if no second line regimens are available</p></li>
<li class="fragment"><p>Failure &gt; 28 days: Likely re-infection: Treat with first-line ACT</p></li>
</ul></li>
<li class="fragment"><p><strong>Treatment failure may result from:</strong></p>
<ul>
<li class="fragment"><p>Drug resistance</p></li>
<li class="fragment"><p>Inadequate exposure to the drug due to sub-optimal dosing, poor adherence, vomiting, unusual pharmacokinetics in an individual,</p></li>
<li class="fragment"><p>Substandard (counterfeited) medicine</p></li>
</ul></li>
</ul>
</section>
<section id="artemisinin-resistance" class="slide level2">
<h2>Artemisinin resistance</h2>
<ul>
<li class="fragment"><p>Southeast Asia, parts of sub-Saharan Africa, South America</p></li>
<li class="fragment"><p>Consider in patients with epidemiological exposure</p></li>
<li class="fragment"><p>Evaluation:</p>
<ul>
<li class="fragment">Malarial blood smear on day 3: Unlikely if parasite density &lt; 3% with initial parasite density of &gt; 100,000 parasites/μL</li>
</ul></li>
</ul>
</section>
<section id="reducing-transmissibility" class="slide level2">
<h2>Reducing transmissibility</h2>

<img data-src="images_malaria/drugstagecycle.png" class="r-stretch quarto-figure-center"></section>
<section id="reducing-transmissibility-1" class="slide level2">
<h2>Reducing transmissibility</h2>
<ul>
<li class="fragment">Gametocytes may persist in blood after successful treatment of infection; not harmful to patient but serve as a source of ongoing transmission</li>
<li class="fragment">Single doses of primaquine &gt; 0.4 mg/kg bw reduced gametocyte carriage at day 8 by around two thirds (moderate- quality evidence).</li>
</ul>
<p><img data-src="images_malaria/transmission.png"></p>
<div>
<p>Avoid in pregnant patients and infants &lt; 6 months</p>

</div>
<aside><div>
<p><span class="citation" data-cites="worldhealthorganization22a">(<a href="#/references" role="doc-biblioref" onclick="">Organization, 2022</a>)</span></p>
</div></aside></section>
<section id="definition-of-severe-malaria-1" class="slide level2">
<h2>Definition of severe malaria</h2>
<table>
<colgroup>
<col style="width: 7%">
<col style="width: 92%">
</colgroup>
<thead>
<tr class="header">
<th>Manifestations</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Impaired consciousness</td>
<td>Glasgow coma score &lt;11 in adults or Blantyre coma score &lt;3 in children; inability to swallow</td>
</tr>
<tr class="even">
<td>Prostration</td>
<td>Generalized weakness so that a person is unable to sit, stand, or walk without assistance</td>
</tr>
<tr class="odd">
<td>Multiple convulsions</td>
<td>More than two episodes within 24 hours</td>
</tr>
<tr class="even">
<td>Acidosis</td>
<td>A base deficit of &gt;8 mEq/L, a plasma bicarbonate level of &lt;15 mmol/L, or venous plasma lactate ≥5 mmol/L. Clinical indicators of acidosis include rapid, deep, labored breathing.</td>
</tr>
<tr class="odd">
<td>Hypoglycaemia</td>
<td>Blood or plasma glucose &lt;40 mg/dL (&lt;2.2 mmol/L) for children ≥5 years and adults; blood or plasma glucose &lt;54 mg/dL (&lt;3 mmol/L) for children &lt;5 years</td>
</tr>
<tr class="even">
<td>Severe anaemia</td>
<td>Haemoglobin concentration ≤5 g/dL or hematocrit ≤15% in children &lt;12 years of age (&lt;7 g/dL and &lt;20%, respectively, in adults) with parasite count &gt;10,000 parasites/uL</td>
</tr>
<tr class="odd">
<td>Renal impairment</td>
<td>Plasma or serum creatinine &gt;3 mg/dL (265 umol/L) or blood urea &gt;20 mmol/L</td>
</tr>
<tr class="even">
<td>Jaundice</td>
<td>Plasma or serum bilirubin &gt;50 umol/L (3 mg/dL) with one of the following:<br>- Plasmodium fal<em>ciparum parasite coun</em>t &gt;2.5% parasitemia<br>- Plasmodium knowlesi parasite <em>count &gt;20,000 para</em>sites/uL</td>
</tr>
<tr class="odd">
<td>Pulmonary edaema</td>
<td>Radiographically confirmed or oxygen saturation &lt;92% on room air with respiratory rate &gt;30/minute, often with chest indrawing and crepitation on auscultation</td>
</tr>
<tr class="even">
<td>Significant bleeding</td>
<td>Including recurrent or prolonged bleeding (from the nose, gums, or venipuncture sites), hematemesis, or melena</td>
</tr>
<tr class="odd">
<td>Shock</td>
<td>Compensated shock is defined as capillary refill ≥3 seconds or temperature gradient on leg (mid to proximal limb), but no hypotension. Decompensated shock is defined as systolic blood pressure &lt;70 mmHg in children or &lt;80 mmHg in adults, with evidence of impaired perfusion (cool peripheries or prolonged capillary refill).</td>
</tr>
<tr class="even">
<td>Hyperparasitaemia</td>
<td><em>P. falciparum</em>:<br>- In non-immune travelers: parasitemia ≥5%[3]<br>- All patients: parasitemia &gt;10%<br><em>P. knowlesi</em>:<br>- Parasite density &gt;100,000 parasites/uL<br><em>Plasmodium vivax</em>:<br>- No established parasite density thresholds</td>
</tr>
</tbody>
</table>
</section>
<section id="treatment-of-severe-malaria" class="slide level2">
<h2>Treatment of severe malaria</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/severemalarai.png"></p>
</figure>
</div>
<div>

<p>Delayed haemolysis starting &gt;1 week after artesunate treatment of severe malaria has been reported in hyperparasitaemic non-immune travellers.</p>
<p>When artesunate not available, artemether is considered as second line therapy followed by quinine (dihyrdochloride)- must be given by slow infusion or IM.</p>

</div><aside><div>
<p><span class="citation" data-cites="worldhealthorganization22a">(<a href="#/references" role="doc-biblioref" onclick="">Organization, 2022</a>)</span></p>
</div></aside></section>
<section id="pre-referral-treatment-options" class="slide level2">
<h2>Pre-referral treatment options</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/prereferrel.png"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="worldhealthorganization22a">(<a href="#/references" role="doc-biblioref" onclick="">Organization, 2022</a>)</span></p>
</div></aside></section>
<section id="prevention-of-malaria-infection-in-travellers" class="slide level2">
<h2>Prevention of malaria infection in travellers</h2>
<ul>
<li class="fragment"><p>Areas chloroquine-resistant <em>P. falciparum</em></p>
<ul>
<li class="fragment"><p>Mosquito avoidance</p></li>
<li class="fragment"><p>Chemoprophylaxis (atovaquone-proguanil, mefloquine, doxycycline, tafenoquine)</p>
<ul>
<li class="fragment"><p>Fewest side effects with atovaquone-proguanil</p></li>
<li class="fragment"><p>Weekly mefloquine</p></li>
<li class="fragment"><p>Doxycycline must be taken daily, sun sensitization</p></li>
<li class="fragment"><p>Test for G6PD deficiency before using tefenoquine</p></li>
</ul></li>
<li class="fragment"><p>Start chemoprophylaxis prior to departure, continued regularly during travel, and continued for a time period after departure (duration is drug dependent)</p>
<ul>
<li class="fragment">Shortest discontinuation time is with atovaquone-proguanil and tafenoquine (one week)</li>
</ul></li>
</ul></li>
<li class="fragment"><p>Other options are available for areas with chloroquine-sensitive <em>P. falciparum</em> or <em>P. vivax</em></p></li>
</ul>
</section>
<section id="vector-control" class="slide level2">
<h2>Vector control</h2>
<p><br></p>
<div class="columns">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/nets.png" width="400"></p>
</figure>
</div><div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="images_malaria/indoor.png" width="400"></p>
</figure>
</div>
</div>
</div>
</section>
<section id="chemoprevention" class="slide level2">
<h2>Chemoprevention</h2>
<p><br></p>
<ul>
<li class="fragment"><p>Seasonal malaria chemoprevention campaigns targeting children &lt; 5 years</p>
<ul>
<li class="fragment"><p>e.g., monthly treatment with sulfadoxine-pyrimethamine treatment during rainy season, &gt; 80% reduction in malaria cases, with &gt; 50% reduction in mortality</p></li>
<li class="fragment"><p>Rebound effect? Child looses immunity, treatment stopped because of age limit, social instability, resistance</p></li>
</ul></li>
</ul>
</section>
<section id="vaccine-prospects" class="slide level2" data-background-image="./images_malaria/vaccine.png" data-background-opacity="0.5">
<h2>Vaccine prospects</h2>

<img data-src="images_malaria/vaccine2.png" width="600" class="r-stretch quarto-figure-center"></section>
<section id="leishmania-infections" class="slide level2" data-background-image="./images_malaria/sandfly.jpeg" data-background-opacity="0.7">
<h2>Leishmania infections</h2>
</section>
<section id="tissue-smear-from-patient-with-leishmania" class="slide level2">
<h2>Tissue smear from patient with <em>Leishmania</em></h2>

<img data-src="images_malaria/leish2.jpeg" width="800" class="r-stretch quarto-figure-center"></section>
<section id="leishmaniasis-classification" class="slide level2">
<h2>Leishmaniasis classification</h2>

<img data-src="images_malaria/leish_class.png" class="r-stretch quarto-figure-center"></section>
<section id="distribution-of-cutaneous-leishmaniasis" class="slide level2">
<h2>Distribution of cutaneous leishmaniasis</h2>

<img data-src="images_malaria/cutaneous.jpeg" class="r-stretch quarto-figure-center"></section>
<section id="distribution-of-visceral-leishmaniasis" class="slide level2">
<h2>Distribution of visceral leishmaniasis</h2>

<img data-src="images_malaria/visceral.jpeg" class="r-stretch quarto-figure-center"></section>
<section id="spectrum-of-leishmania-infection-and-disease" class="slide level2">
<h2>Spectrum of Leishmania infection and disease</h2>

<img data-src="images_malaria/spectrum.jpeg" class="r-stretch quarto-figure-center"></section>
<section id="pathophysiology" class="slide level2">
<h2>Pathophysiology</h2>
<p><br></p>
<ul>
<li class="fragment"><p><em>Leishmania</em> invade and replciate inside host macrophages</p></li>
<li class="fragment"><p>Many infections are asymptomatic (subclinical), reflecting the host ability to control the infection</p></li>
<li class="fragment"><p>Subclinical infections can reactive during periods of immunosuppression</p></li>
</ul>
</section>
<section id="classic-presentation-of-vl-kala-azar" class="slide level2">
<h2>Classic presentation of VL (kala-azar)</h2>
<ul>
<li class="fragment">Prolonged fever</li>
<li class="fragment">Weight loss</li>
<li class="fragment">Hepato- splenomegaly
<ul>
<li class="fragment">Parasite replicate in reticuloendothelial system (RES), with high parasite loads accumulating in liver, spleen and bone marrow</li>
</ul></li>
<li class="fragment">Pancytopenia (due to bone marrow suppression)</li>
<li class="fragment">Hypergammaglobinumia (polyclonal B cell activation)</li>
<li class="fragment">Late in course of infection thrombocytopenia and liver dysfunction</li>
<li class="fragment">Uniformly lethal without treatment</li>
</ul>
</section>
<section id="clinical-manifestations" class="slide level2">
<h2>Clinical manifestations <br></h2>
<ul>
<li class="fragment">incubation period (2-8 months) but can be as short as 8 10 days</li>
<li class="fragment">Clinical disease may first become symptomatic years after exposure in patients who are immunocompromised</li>
<li class="fragment">Insidious development: fever, weakness, loss of appetite, weightloss, failure to thrive, abdominal enlargement caused by hepatosplenomegaly</li>
<li class="fragment">Acute presentation in non-immune patients with high fever and chills, sometimes with a periodicity suggestive of malaria
<ul>
<li class="fragment">Spleen can become massively enlarges, soft and non-tender -Elevated liver enzymes and bilirubin occasionally present</li>
</ul></li>
<li class="fragment">Patients often become cachectic with petechia and ecchymoses with possible epistaxis and gingival bleeding</li>
</ul>
</section>
<section id="protruding-abdomen-with-hepatosplenomegaly" class="slide level2">
<h2>Protruding abdomen with hepatosplenomegaly</h2>

<img data-src="images_malaria/hepatomegaly.jpeg" class="r-stretch quarto-figure-center"></section>
<section id="diagnosis-pentad" class="slide level2" data-background-image="./images_malaria/donkey.png" data-background-opacity="0.7">
<h2>Diagnosis Pentad</h2>
<p><br></p>
<ul>
<li class="fragment">Prolonged fever</li>
<li class="fragment">Progressive weight-loss</li>
<li class="fragment">Pronounced spelnomegaly</li>
<li class="fragment">Pancytopenia</li>
<li class="fragment">Hypergammaglobulinemia</li>
</ul>
</section>
<section id="diagnosis-confirmation" class="slide level2">
<h2>Diagnosis confirmation</h2>
<ul>
<li class="fragment">Parasitologic diagnosis: Amastigotes in tissues</li>
<li class="fragment">Isolation of promastigotes in cultures</li>
<li class="fragment">Splenic aspiration, liver biopsy, lymph node or bone marrow aspirates (safer but lower sensitivity)</li>
<li class="fragment">PCR assay</li>
<li class="fragment">Antileishmanial antibodies</li>
</ul>
</section>
<section id="treatment" class="slide level2">
<h2>Treatment</h2>
<p><br></p>
<ul>
<li class="fragment">Liposomal amphotericin B 10 mg/kg two consecutive days or 3 mg/kg days 1-5, 14, and 21</li>
<li class="fragment">Amphotericin B deoxycholate 1 mg/kg for 15 days or 1 mg/kg every other day for 30 days</li>
<li class="fragment">Pentamidine (hypotension, hypoglycaemia, insulin-dependent diabetes mellitus)</li>
<li class="fragment">Miltefosine (oral, GI toxicity, elevated liver transaminases)</li>
</ul>
</section>
<section id="treatment-response" class="slide level2">
<h2>Treatment response</h2>
<p><br></p>
<ul>
<li class="fragment">Fever resolution (1-2 weeks)</li>
<li class="fragment">Decrease in spleen size over 1 month</li>
<li class="fragment">Weight gain</li>
<li class="fragment">Patients need to be followed for 12 month and instructed to return if symptoms recur.</li>
</ul>
</section>
<section id="references" class="slide level2 smaller scrollable">
<h2>References</h2>
<p><br></p>

<div class="footer footer-default">

</div>
<div id="refs" class="references csl-bib-body" role="list">
<div id="ref-dondorp2011" class="csl-entry" role="listitem">
Dondorp AM, Fairhurst RM, Slutsker L, MacArthur JR, M. D. JGB, Guerin PJ, et al. The threat of artemisinin-resistant malaria. New England Journal of Medicine 2011;365:1073–5. <a href="https://doi.org/10.1056/NEJMp1108322">https://doi.org/10.1056/NEJMp1108322</a>.
</div>
<div id="ref-fairhurstrick2015" class="csl-entry" role="listitem">
Fairhurst, Rick, Wellems, Thomas. Malaria (plasmodium species). 8th ed., Elsivier; 2015.
</div>
<div id="ref-idro2005" class="csl-entry" role="listitem">
Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. The Lancet Neurology 2005;4:827–40. <a href="https://doi.org/10.1016/S1474-4422(05)70247-7">https://doi.org/10.1016/S1474-4422(05)70247-7</a>.
</div>
<div id="ref-kwiatkowski2005" class="csl-entry" role="listitem">
Kwiatkowski DP. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1224522/">How malaria has affected the human genome and what human genetics can teach us about malaria</a>. American Journal of Human Genetics 2005;77:171–92.
</div>
<div id="ref-worldhealthorganization22a" class="csl-entry" role="listitem">
Organization WH. <span>WHO Guidelines</span> for <span>Malaria</span> 2022.
</div>
<div id="ref-phillips2017" class="csl-entry" role="listitem">
Phillips MA, Burrows JN, Manyando C, Huijsduijnen RH van, Van Voorhis WC, Wells TNC. Malaria. Nature Reviews Disease Primers 2017;3:17050. <a href="https://doi.org/10.1038/nrdp.2017.50">https://doi.org/10.1038/nrdp.2017.50</a>.
</div>
<div id="ref-tatem2006" class="csl-entry" role="listitem">
Tatem AJ, Rogers DJ, Hay SI. Estimating the malaria risk of african mosquito movement by air travel. Malaria Journal 2006;5:57. <a href="https://doi.org/10.1186/1475-2875-5-57">https://doi.org/10.1186/1475-2875-5-57</a>.
</div>
</div>
</section>
    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="site_libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="site_libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="site_libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="site_libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="site_libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="site_libs/revealjs/plugin/reveal-chalkboard/plugin.js"></script>
  <script src="site_libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="site_libs/revealjs/plugin/notes/notes.js"></script>
  <script src="site_libs/revealjs/plugin/search/search.js"></script>
  <script src="site_libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="site_libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': false,
'previewLinksAuto': false,
'smaller': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleChalkboard(event)\"><kbd>b</kbd> Toggle Chalkboard</a></li>\n<li class=\"slide-tool-item\" data-item=\"5\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleNotesCanvas(event)\"><kbd>c</kbd> Toggle Notes Canvas</a></li>\n<li class=\"slide-tool-item\" data-item=\"6\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.downloadDrawings(event)\"><kbd>d</kbd> Download Drawings</a></li>\n<li class=\"slide-tool-item\" data-item=\"7\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'chalkboard': {"buttons":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: true,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: 'c/t',

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'fade',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'fast',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, RevealChalkboard, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button', {
        text: function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
      });
      clipboard.on('success', function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "Copied!");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "Copied!");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      });
      function tippyHover(el, contentFn) {
        const config = {
          allowHTML: true,
          content: contentFn,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start'
        };
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          return note.innerHTML;
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    

</body></html>